Realbotix lands up-to-$5M merger bridge loan from Onconetix
What's the deal? Realbotix Corp.Dealroom has a profile for this one. Try Dealroom → (TSX-V: XBOT), a humanoid robotics and embodied AI company, said its subsidiary Realbotix LLC entered an unsecured bridge loan of up to US$5 million with Onconetix, Inc.Dealroom has a profile for this one. Try Dealroom → The facility carries an initial draw of US$2.5 million and provides working capital while the two advance a proposed merger.
Why now? The loan ties back to a merger the parties first announced on February 12, 2026. Onconetix is the lender, Realbotix LLC the borrower, and Realbotix Corp. guarantees payment.
How it works: The note is non-interest bearing. If the merger closes, the note and all obligations are automatically cancelled in full, with no payment required. Should the merger agreement be terminated, interest accrues on the outstanding principal at 12% per annum from the termination date.
What's the endgame? Realbotix builds US-made humanoid robots and embodied AI systems for healthcare, education, service industries, and consumer markets. Its patented technology enables lifelike facial expressions, fluid movement, and vision systems.
In their words: "The loan provides working capital for Realbotix LLC during the merger process, and preserves the economic alignment between Realbotix and Onconetix," said Andrew Kiguel, chief executive officer of Realbotix.
What could go wrong? The financing hinges on the merger. If the deal falls apart, the forgivable note flips into interest-bearing debt at 12%. A negative covenant also bars Realbotix from taking on additional debt without Onconetix's consent.
The signal: At US$5 million, this is a modest, transaction-linked facility rather than a growth raise — a stopgap to keep a small robotics firm funded while its merger clears. It shows how cash-tight scaleups are structuring financing around deal outcomes rather than open-market terms.
Read more: stocktitan.net
Image credit: Generated with Gemini
